In the control experiment, cannulated arterioles were bathed in physiologic saline solution (PSS) at a temperature between 36°C and 37°C for 30 to 40 minutes to facilitate the development of basal tone. After the basal tone developed, we evaluated the effect of B(e)P on the nitric oxide (NO)-mediated vasodilation. To accomplish this, the endothelium-dependent NO-mediated vasodilation in response to bradykinin (range, 1 pM–10 nM) was established before and after 180 minutes of intraluminal incubation with 100 μM B(e)P (
n = 6). The vessels were exposed to each concentration of bradykinin for 2 to 3 minutes until a stable diameter was established. In a preliminary study, we found that the vasodilation that occurs with exposure to bradykinin was reproducible and sustained after repeated applications (
n = 6). In another series of studies, to determine whether the effect of B(e)P is a selective response to endothelium-dependent NO-mediated vasodilation, the dose-dependent responses to the receptor-independent but endothelial NO-mediated vasodilator A23187 (range, 10 nM–3 μM;
n = 6) and to endothelium-independent NO-donor sodium nitroprusside (SNP; range, 10 nM–100 μM;
n = 6) were established before and after 180 minutes of intraluminal incubation of 100 μM of B(e)P. In each separate group of vessels, the roles of superoxide and oxidative enzymes xanthine oxidase and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in mediating the adverse effects of B(e)P were determined by evaluating bradykinin-induced vasodilation before and after treating the vessels with B(e)P (100 μM) combined with superoxide production pathway inhibitors, such as the cell-permeable superoxide scavenger, 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL; 1 mM;
n = 6),
19 the xanthine oxidase inhibitor allopurinol (10 μM;
n = 6),
20 or the NADPH oxidase inhibitor apocynin (100 μM;
n = 6).
19 The roles of stress-activated protein kinase were examined by evaluating bradykinin-induced vasodilation before and after treating the vessels with B(e)P combined with the c-Jun N-terminal kinase (JNK) inhibitor SP600125 (5 μM;
n = 8),
21 the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 (0.1 μM;
n = 8),
22 or coadministration of SP600125 and SB203580 (
n = 8). To determine if genistein and RSV, which protect against oxidative stress, mitigated the action of B(e)P on the NO-mediated vasodilation, the arterioles were evaluated by bradykinin-induced vasodilation before and after treating the vessels with B(e)P (100 μM) combined with genistein (30 μM;
n = 8) or RSV (1 μM;
n = 8).